| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion |
| 28 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 28, 2026, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28,... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million |
| 28 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(e) As discussed below in Item 5.07, Neurocrine Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved an amendment of the Company’s 2025 Equity ... |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., CITIBANK, N.A., GOLDMAN SACHS BANK USA and WELLS FARGO BANK, NATIONAL ASSOCIATION, |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year |
| 06 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), is made and entered into as of April 5, 2026, by and among Neurocrine Biosciences, Inc., a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a direct... |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 |
| 24 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amendment to Amended and Restated Employment Agreement (this “Amendment”), is made as of November 21, 2025, by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewo... |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth |
| 30 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into as of May 30, 2025 and made effective as of the Effective Date (defined in Annex I) by a... |
| 22 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(e) As discussed below in Item 5.07, Neurocrine Biosciences, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved: (i) the Company’s 2025 Equity Incentive P... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion |
| 04 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN DIEGO, April 4, 2025 -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company’s executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswan... |
| 06 Feb 2025 |
8-K: Results of Operations and Financial Condition
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively |
| 27 Jan 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) |
| 20 Dec 2024 |
8-K: Other Events
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia |
| 01 Nov 2024 |
8-K: Other Events
On October 31, 2024, Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”) entered into an accelerated share repurchase (“ASR”) transaction under an agreement (the “ASR Agreement”) with Goldman Sachs & Co. LLC (“GS&Co.... |
| 30 Oct 2024 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, October 30, 2024 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. |
Loading...